Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272064 | 0.80 | TP53 (0.35) | TP53PSIP1 | |
| SCHEMBL704628 | 0.77 | LTA4H (0.35) | TP53CES2CES1TSHRALOX12 | |
| SCHEMBL11152840 | 0.75 | LTA4H (0.36) | TP53CES2CES1 | |
| SCHEMBL2101606 | 0.75 | KCNH2 (0.38) | TSHRALDH1A1 | |
| SCHEMBL2100218 | 0.75 | HTT (0.33) | TP53KCNN4 | |
| SCHEMBL27290628 | 0.74 | LOXL2 (0.38) | TSHRALOX12ALDH1A1 | |
| SCHEMBL2102293 | 0.73 | KDM4E (0.38) | LMNATSHRATMKCNN4 | |
| SCHEMBL9702347 | 0.73 | MAOA (0.33) | — | |
| SCHEMBL2100800 | 0.73 | ALDH1A1 (0.39) | LMNATSHRALDH1A1HIF1A | |
| SCHEMBL7052676 | 0.73 | RIPK1 (0.32) | LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103665025-B | The synthetic method of adamantyl benzocyclobutene monomer and polymer thereof | 复旦大学 | 2016-07-06 | — | — | CN | claimed |
| CN-103665025-A | Adamantyl benzocyclobutene monomer and synthesizing method of polymer of adamantyl benzocyclobutene monomer | UNIV FUDAN | 2014-03-26 | — | — | CN | claimed |
| CN-103665025-B | The synthetic method of adamantyl benzocyclobutene monomer and polymer thereof | 复旦大学 | 2016-07-06 | — | — | CN | disclosed |
| EP-2599836-B1 | CURABLE COMPOSITION FOR SEMICONDUCTOR ENCAPSULATION | ADEKA CORP (JP) | 2015-03-25 | — | — | EP | disclosed |
| CN-102471581-B | Curable composition for semiconductor encapsulation | ADEKA CORP | 2015-01-28 | — | — | CN | disclosed |
| US-8871890-B2 | Curable resin composition and cured article | DAICEL CORPORATION (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8791221-B2 | Addition-curable metallosiloxane compound | DAICEL CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| CN-103665025-A | Adamantyl benzocyclobutene monomer and synthesizing method of polymer of adamantyl benzocyclobutene monomer | UNIV FUDAN | 2014-03-26 | — | — | CN | disclosed |
| EP-2650319-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | Daicel Corporation (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | DAICEL CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| EP-2636706-A1 | CURABLE RESIN COMPOSITION AND CURED ARTICLE | Daicel Corporation (JP) | 2013-09-11 | — | — | EP | disclosed |
| EP-0547774-A1 | Process for disproportionation of arylsilanes | DOW CORNING CORPORATION (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0540580-A1 | POLYMERIC DRUG DELIVERY SYSTEM. | SEARLE & CO (US) | 1993-05-12 | — | — | EP | disclosed |
| EP-0539039-A1 | Thermal disproportionation of arylhalosilanes | DOW CORNING CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| US-5136070-A | Sodium borohydride catalyzed disproportionation of cycloorganosilanes | DOW CORNING CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| US-5136071-A | Reduces induction time | DOW CORNING CORPORATION (US) | 1992-08-04 | — | — | US | disclosed |
| US-5110974-A | Thermal disproportionation of arylhalosilanes | DOW CORNING CORPORATION (US) | 1992-05-05 | — | — | US | disclosed |
| US-4537983-A | HYDROGEN CHLOROSILANES ARE REACTED WITH STYRENE IN THE PRESENCE OFF BENZOTHZAZOLE AND A PLATIUM CATALYST | DYNAMIT NOBEL AG (DE) | 1985-08-27 | — | — | US | disclosed |
| US-4476291-A | Resins containing β-phenylethyl trifunctional siloxy units and method for making | GENERAL ELECTRIC COMPANY (US) | 1984-10-09 | — | — | US | disclosed |
| US-4417069-A | FROM STYRENE AND CHLOROSILANE, PLATINUM CATALYST AND TERTIARY AMINE | GENERAL ELECTRIC COMPANY (US) | 1983-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267653-A1 | ADDITION-CURABLE METALLOSILOXANE COMPOUND | B2M, MSI2, MNS1 | TP53 3501/4885PSIP1 3004/4885CES2 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.